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Familial Adult Myoclonic Epilepsy (FAME) is characterised by cortical myoclonic tremor
usually from the second decade of life and overt myoclonic or generalised tonic-clonic sei-
zures. Four independent loci have been implicated in FAME on chromosomes (chr) 2, 3, 5
and 8. Using whole genome sequencing and repeat primed PCR, we provide evidence that
chr2-linked FAME (FAME2) is caused by an expansion of an ATTTC pentamer within the first
intron of STARD7. The ATTTC expansions segregate in 158/158 individuals typically affected
by FAME from 22 pedigrees including 16 previously reported families recruited worldwide.
RNA sequencing from patient derived fibroblasts shows no accumulation of the AUUUU or
AUUUC repeat sequences and STARD7 gene expression is not affected. These data, in
combination with other genes bearing similar mutations that have been implicated in FAME,
suggest ATTTC expansions may cause this disorder, irrespective of the genomic locus
involved.
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FAME (also referred to as Familial Cortical Myoclonic Tre-mor and Epilepsy or Benign Adult onset Familial MyoclonicEpilepsy [OMIM phenotypic series: PS601068]) is char-
acterised by cortical myoclonic tremor and overt myoclonic and
later generalised tonic-clonic seizures (GTCS)1. Onset of symp-
toms occurs in the second to third decade with variable expres-
sivity within and between families; anticipation has been noted in
some families1. The frequency of GTCS varies from 15 to 100% in
22 different families reported here (Table 1)2. Seizures are typi-
cally controlled with anti-epileptic drugs for generalised epi-
lepsies, although rarely individuals have drug resistant epilepsy.
FAME has been mapped to four distinct chromosomal loci. Most
families link to chromosomes 8q243 or 2p11.2-q11.24, with an
additional two families mapping to chromosome 5p15.31-p155
and one to chromosome 3q26.32-q286. There is one report of
autosomal recessive FAME caused by mutation in CNTN2 where
the phenotype was disputed7,8. Candidate genes and variants that
fall within these common linkage intervals have been suggested
for chr2 (ADRA2B) and chr5 (CTNND2); however, none of these
genes have been shown to be allelic in all FAME families with
linkage to the same interval1. We previously showed using
identity-by-descent mapping that there are at least four distinct
founder loci linked to FAME2 (OMIM:607876) on chr29.
The genetic cause of FAME has long remained elusive. The
cause of FAME1, which is linked to chr8 (OMIM:601068), has
recently been shown to be a complex repeat expansion of pen-
tameric TTTTA and inserted TTTCA repeats into the fourth
intron of the SAMD12 gene10,11. In the same study, TNRC6A
(chr16) and RAPGEF2 (chr4) were implicated as FAME genes
within single families, respectively, found via direct detection of
the same repeated TTTTA and TTTCA sequences11.
Here, we use bioinformatic analysis of short-read whole-gen-
ome sequencing to identify ATTTT and ATTTC repeat
expansions in the FAME2 linkage interval. We screen for an
intronic ATTTC expansion in the first intron of STARD7 by
repeat-primed PCR and show it segregates with FAME2 in 158
affected individuals from 22 families. We use long-read sequen-
cing to suggest the ATTTT and ATTTC expansions may be
somatically unstable. We analyse clinical data and show evidence
of anticipation over multiple generations of a large FAME2
family. Finally, we demonstrate that the presence of the ATTTC
repeat has no effect on protein or mRNA expression levels of
STARD7 in available patient cell lines. These data suggest the
repeat sequence alone is pathogenic, independent of an effect on
the coding sequence of the encompassing gene.
Results
Discovery of a repeat expansion in STARD7. We analysed
Illumina HiSeq X-10 whole-genome sequencing data initially from
two individuals from a large Australian-New Zealand FAME
family, one from an Italian family and three from a French-
Spanish family (Table 1 and Supplementary Table 1; Families 1, 3
and 19, respectively)2,12,13 with two repeat expansion detection
methods, ExpansionHunter and exSTRa14,15, to look for similar
combined ATTTT and ATTTC repeat expansions on both the
forward and reverse chromosome strands within the FAME2
interval. This revealed an expansion of an ATTTT repeat and
insertion of an ATTTC repeat in the context of the reverse strand
of chr2 within the first intron of STARD7 (StAR-related lipid
transfer domain-containing 7) in all FAME samples tested
(Fig. 1a, Supplementary Fig. 1). The endogenous ATTTT repeat in
intron 1 of STARD7 was also found to be variable in length in the
normal population but not expanded to the same extent as repeats
found in individuals with FAME. The ATTTC repeat was not
present in any whole-genome sequencing data from 69 control
Table 1 Clinical summaries of 22 investigated FAME families
Family Nationality Total affected Mean onset [range] Myoclonus/CT TCS Focal Sz References
1 Australian/New Zealand of
European ancestry
55 18.6 y [4–59,60 y] 55/55 (100%) 8/55 (15%) 2/55 (4%) 2
2 Italian 2 15–25 y 2/2 (100%) 2/2 (100%) 0/2 (0%)
3 Italian 4 2–18y 4/4 (100%) 4/4 (100%) 2/4 (50%) 12
4 Italian 11 22.3 y [12–49,50 y] 11/11 (100%) 11/11 (100%) 3/11 (27%) 4,17
5 Italian 25 26.6 y [5–39,40 y] 25/25 (100%) 10/25 (40%) 0/25 (0%) 38
6 Italian 12 (3 studied) 12 y [8–17,18 y] 11/12 (91.6%) 6/12 (50%) 1/12 (8.3%) 9,39
7 Italian 4 22.75 y [10–35,36 y] 4/4 (100%) 3/4 (75%) 0/4 (0%)
8 Italian 10 (6 studied) 18.5 y [17–19,20 y] 6/6 (100%) 4/6 (66.6%) 0/6 (0%) 40
9 Italian 13 (11 studied) 17 y [12–21,22 y] 11/11 (100%) 9/11 (81.1%) 0/14 (0%) 41
10 Italian 16 (14 studied) 15.8 y [13–19,20 y] 14/14 (100%) 10/14 (71%) 0/14 (0%) 41
11 Italian 10 (5 studied) 15.5 y [13–17,18 y] 5/5 (100%) 4/5 (80%) 0/5 (0%) 42
12 Italian 21 (17 studied) 39.2 y [24–55,56 y] 17/17 (100%) 13/17 (76.4%) 0/17(0%) 43
13 Italian 3 17.7 y [12–22,23 y] 3/3 (100%) 1/3 (33%) 0/3 (0%) 42,44
14 Italian 3 16.3 y [15–18 y] 3/3 (100%) 3/3 (100%) 0/3 (0%) 44,45
15 Italian 4 30.3 y [18–48,49 y] 4/4 (100%) 3/4 (75%) 2/4 (50%) 17
16 Iraqi of Sephardic Jewish
ancestry
15 (10 studied) 21 y [12–31,32 y] 10/10 (100%) 4/10 (40%) 2/10 (20%)
17 Israeli of Sephardic Jewish
ancestry
2 21 y [21 y] 2/2 (100%) 2/2 (100%) 0/2 (0%)
18 South African of European
ancestry
24 (15 studied) 15.8 y [11–19,20 y] 15/15 (100%) 7/15 (47%) 1/15 (7%) 46
19 French/ Spanish 13 41 y [30–59,60 y] 13/13 (100%) 8/13 (62%) 0/13 (0%) 13,47
20 French 7 (2 studied) 20 y (n= 1) Childhood
(n= 1)
2/2 (100%) 1/2 (50%) 0/2 (0%) 9
21 Syrian 1 20 y 1/1 (100%) 1/1 (100%) 0/1 (0%)
22 Italian 11 (10 studied) 25.1 y [14–39,40 y] 9/10 (90%)a 4/10 (40%) 1/10 (10%)
CT cortical tremor, Focal Sz focal seizures, TCS tonic-clonic seizures, y years, n number of individuals
aOne family member last evaluated at 9 years of age
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samples (Supplementary Fig. 1), nor is it reported in the Simple
Repeats track in the UCSC genome browser (build hg38)16.
Segregation of STARD7 ATTTC expansions by repeat-primed
PCR. We developed a repeat-primed PCR (RP-PCR) assay to
rapidly identify the expansion in 137/137 affected individuals
from 16 independently reported FAME2 families worldwide
(Fig. 1c, d, Table 1, Supplementary Table 1, Supplementary
Data 1, Supplementary Fig. 2; Families 1, 3–6, 8–10, 12–16, 19, 20
and 22). Of the 24 individuals tested in these families that did not
have a FAME diagnosis, two were positive for the ATTTC
expansion; both were from younger generations and likely pre-
symptomatic. We tested an additional 72 individuals (52 unre-
lated and 20 cases from six families with multiple affected
individuals) with clinical similarity to FAME. Of these, 20/20
familial and 1/52 singleton cases were positive for an ATTTC
expansion in STARD7 (Table 1, Supplementary Fig. 2; Families 2,
7, 11, 17, 18 and 21 [singleton case]). The 52 unrelated subjects
comprised 13 subjects with generalised epilepsy and tremor and
39 with myoclonic epilepsy with onset over the age of 19 years; 8/
52 cases had a family history of epilepsy. Finally, within the
families we tested, there were 13 individuals where the diagnosis
of FAME was uncertain, usually due to a history of tremor with
no other diagnostic features. Of these, 8/13 carried the ATTTC
expansion. Two of the individuals with uncertain diagnosis that
tested negative, were a mother and daughter pair from Family 1
(Supplementary Fig. 2a [red box] III-13 and IV-65) and
subsequent analyses with microsatellite markers showed that
these individuals did not have the same haplotype as affected
carriers of the ATTTC expansion (Supplementary Fig. 3). The
ATTTC repeat expansion did not amplify in any of 28 control
DNA samples extracted from unaffected individuals unrelated
to FAME.
In all 158 individuals that tested positive for the ATTTC
expansion, we observed that priming from ATTTT repeats was
only successful from the telomeric end of the endogenous repeat
and priming from ATTTC repeats was only possible from the
centromeric end of the endogenous repeat. This suggested the
structure of the pathogenic repeat in the context of the forward
strand of chr2 was (AAATG)n[N](AAAAT)n, where (n)
represents the unknown number of each repeat sequence.
Long-read sequencing reveals the repeat structure. The total
numbers of repeats could not be determined by the RP-PCR
assay, therefore we investigated some of these with long-read
sequencing (Fig. 2). In one individual from the Australian-New
Zealand family (Family 1: IV-98) a single molecule real-time
(SMRT) read and a single Oxford Nanopore read were found that
spanned the repeat. The SMRT read generated to 99% base
accuracy by circular consensus calling was comprised of four
subreads and contained 274 AAATG and 387 AAAAT repeats,
without interruption from other sequences. The Oxford Nano-
pore read contained 345 AAATG and 390 AAAAT repeats with











+ – + –
22 184 158 0 2 24
96,185,000 96,190,000 96,195,000 96,200,000 96,205,000 96,210,000
STARD7
Simple repeats







































0 50 100 150 0 250 500




























p25.2 p24.3 p24.1 p23.2 p22.2 p21 p16.3 p16.1 p14 p13.2 p12 p11.2 q11.1 q12.1 q13 q14.2 q21.1 q22.1 q22.3 q23.3 q24.2 q31.1 q31.3 q32.2 q33.1 q33.3 q34 q35 q36.2 q37.1 q37.3
96,86296,862,880 bp96,862,860 bp96,862,840 bp
149 bp
96,862,820 bp96,862,800 bp96,862,780 bp96,862,760 bp
STARD7
2q11.2
Fig. 1 Identification of an expanded pentameric ATTTC repeat causing FAME2. a Estimated sizes of the AAATG repeats in two affected individuals from
Family 1 (red, orange), one from Family 3 (brown) and three affected individuals from Family 19 (blue, green, purple), compared to 69 individuals without
FAME using TruSeq Nano (grey) or KAPA Hyper (tan) library preparation. Left panel shows empirical cumulative distribution functions from exSTRa panel
while the right panel shows the estimated repeat size by Expansion Hunter (the sum of both alleles suggests repeat sizes of 0.75–2.3 kb). Data underlying
this part of the figure are available in Source Data. b WGS data from two individuals in Family 1 and one from Family 3 show reads suggesting expansion of
AAAAT and insertion of AAATG repeats in the chr2 linkage interval. c Upper section shows the location of the repeat in the context of chr2. The
approximate location of the FAME2 minimal linkage interval is shown above the ideogram with two blue arrow heads. The STARD7 gene is on the reverse
chromosome strand and the endogenous AAAAT repeat is found in the first intron of the gene. Schema in the lower section shows the primers used in the
RP-PCR to detect the ATTTT “3′ assay” and ATTTC “5′ assay” expanded repeats, respectively. d Example results of the RP-PCR 5′ assay obtained in an
individual negative for the ATTTC insert (top panel) and in an individual affected by FAME, positive for the ATTTC repeat insertion (bottom panel). Full
screening results are provided in Supplementary Data 1. e Summary of 184 individuals from 22 families tested with the RP-PCR assay. Individuals under
category (+) tested positive for the ATTTC repeat and individuals under category (−) tested negative for the repeat
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may occur within the one individual. In a second individual
(Family 5; III-37), a single Oxford Nanopore read spanned the
expanded repeats with 588 AAATG and 340 AAAAT repeats;
4645 bp in total length. The natural variability in the length of the
endogenous ATTTT repeat sequence meant that is was not fea-
sible to use that sequence for mutation screening; however, the
ATTTC repeat primer was diagnostic for FAME with a sensitivity
of 100% in all families with linkage or suggestive linkage to chr2.
This included two families with the previously identified
ADRA2B; c.675_686delTGGTGGGGCTTTinsGTTTGGCAG; p.
H225_L229delinsQ225_F_G_R228 variant strongly suggesting
that allele is not causative (Table 1; Family 4 & 15)17.
Evidence of anticipation in a large FAME2 family. In view of
the discovery that FAME2 and FAME1 are caused by similar
dynamic mutations of ATTTC repeats, and the demonstration of
clinical anticipation in FAME111, we searched for evidence of
anticipation in our pedigrees. We examined the median onset age
of any relevant symptom, where available, for each generation in
the Australian/New Zealand family (Family 1). We found evi-
dence of anticipation; generation III had a median onset of
30 years (range 14–60 y, n= 6), in generation IV median onset
was 17 years (8–50 y, n= 30) and the median onset in generation
V was 12 years (4–19 y, n= 16). The remaining families were
either too small or onset data were unavailable for anticipation to
be robustly assessed.
STARD7 transcript and protein abundance are not altered.
Reverse transcriptase, quantitative PCR using primer pairs span-
ning the repeat containing intron between exons one and two and
a second pair spanning between exons three and four showed no
significant differences in STARD7 transcript expression in patient-
derived fibroblast cell lines (Fig. 3a). Protein abundance was also
unaltered, confirmed by western blotting using an antibody to
STARD7 protein that was previously validated using STARD7-
knockout cell lines (Fig. 3b)18. RNA-Seq data from six patient-
derived fibroblasts (four from Family 1 and two from Family 5)
showed there was no significant difference in gene expression of
STARD7 between affected and unaffected individuals along the
entire length of the gene (Supplementary Fig. 4; p= 0.838; False
Discovery Rate= 1). Reads containing ATTTC repeats were not
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Fig. 2 Long-read sequencing identifies the structure of the AAATG/AAAAT repeat expansion in intron one of STARD7. a Upper panel shows CCS reads
from one member of Family 1 (IV-98) mapped to GRCh38. A read with a 3261 bp insert (blue arrow) which contains both AAATG and AAAAT sequences
and flanking sequences that map to either side of the endogenous AAAAT repeat is present. Lower panel shows the component subreads mapped to the
same region. b Top panel shows combined PacBio and nanopore reads mapped to hg38, following correction with Canu v1.7, with base pair mismatches in
the reads masked for clarity. For Family 1 IV-98 (upper panel), a 2154 bp insert is shown (black arrow) on IGV; however, the read sequence contains a
3672 bp combined AAATG/AAAAT repeat insertion. Lower panel shows a nanopore read in one individual from Family 5 (II-37) with a 1705 bp insert on
IGV (blue arrow), however the read contains a 4645 bp combined AAATG/AAAAT repeat insertion. Complete sequences for all reads that span the
repeat expansion are included in Supplementary Data
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STARD7. This is consistent with the observations from lympho-
blastoid cell lines (LCLs) derived from individuals with FAME1,
where no reads with repeats were found11.
Discussion
The pathogenic ATTTC insertion and expansion was always
accompanied by the endogenous ATTTT pentanucleotide repeat
in all cases of FAME2 that we describe here, replicating the
findings in the cases of FAME with expansions in SAMD12,
TNRC6A, RAPGEF210,11,19 and the report of a similar expansion
in MARCH6 causing chr5-linked FAME20. The same observation
also holds for spinocerebellar ataxia 37 (SCA37, OMIM: 615945),
which is caused by the same repeat expansion in the first intron of
DAB121. For SCA37, it has been hypothesised that the thymidine
to cytosine transition occurs after expansion of the endogenous
ATTTT repeat to ~200 copies followed by further expansion of
the mutant ATTTC sequence22. The ATTTT/ATTTC strand of
the repeat is aligned with the direction of gene expression in all
genes reported thus far, regardless of their chromosomal orien-
tation. The mechanism of disease pathogenesis has been sug-
gested to be RNA toxicity21. In zebrafish embryos, direct injection
of RNA containing 58 copies of the AUUUC repeat was lethal or
caused developmental defects in 81%, while the effect of injecting
RNA containing 139 AUUUU repeats was not significantly dif-
ferent from controls21. Accumulation of AUUUC repeat con-
taining RNA was observed in the brain of some individuals with
FAME1, but we did not have access to similar biopsy tissue from
individuals with FAME211. While we found no significant change
in expression of STARD7 in patient-derived cell lines, it is pos-
sible that expression of this gene is regulated differently in the
non-proliferating cells of the brain. Profiling expression of all
known genes implicated with pathogenic ATTTC dynamic
mutations using gene expression data from the GTEX portal
https://www.gtexportal.org23 shows that DAB1 has high expres-
sion specifically in cerebellum while the five genes implicated in
FAME thus far are more broadly expressed throughout the brain
(Fig. 4). This difference in expression may partly explain the
absence of epilepsy in individuals with SCA37.
STARD7 is a member of the START (StAR-related lipid
transfer) domain-containing family of lipid transfer proteins with
functions including intra-mitochondrial lipid transfer of phos-
phatidylcholine24. Previously, increased levels of choline have
been detected by proton magnetic resonance spectroscopy (1H-
MRS) in the cerebellum of 11 individuals from three Italian
families all shown here to have the ATTTC dynamic mutation25
(Table 1). This observation may be peculiar to FAME2 families
since the SAMD12, RAPGEF2, TNRC6A and MARCH6 genes do
not have overlapping molecular functions.
In conclusion, we have identified the molecular basis of
FAME2 is an inserted expanded ATTTC repeat in the first intron
of the STARD7 gene, in 22 pedigrees with 266 affected indivi-
duals. The insertion segregates with disease status in 100% of
individuals tested from families with linkage or suggestive linkage
to chromosome 2 providing substantial genetic evidence that this
mutation is causal in this syndrome. The FAME2 locus is the
most frequently observed linked region for Caucasian individuals
affected by this disorder whereas chromosome 8 thus far is lim-
ited to Asian individuals, therefore molecular genetic testing
should take this into consideration if choosing to screen by RP-
PCR. Identification of the gene and causative mutation for
FAME2 opens the opportunity to explore the origins of the
ATTTT/ATTTC expansion through a detailed comparison of the
haplotypes and repeat structures of these individuals as has been
done for SCA3722. There may be many additional undiagnosed
individuals with a spectrum of FAME-related symptoms whose
genetic causes may be due to ATTTC insertion and expansion at
one of the FAME loci. This is especially likely in families that
have multiple individuals with tremor and a low frequency of
GTCS. As no preventive or curative treatments are currently
available for FAME, these findings may have important ther-
apeutic implications, including RNA-targeting treatments, such
as antisense oligonucleotides or RNA-targeting Cas9 (RCas9)26.
Methods
Ethics. This study was approved by the Human Research Ethics Committees of the
University of Melbourne and the University of Adelaide. Written, informed con-
sent was obtained from all participants in the study.
Whole-genome sequencing. Adelaide: Human genomic DNA extracting from
peripheral blood lymphocytes was prepared from two individuals in Family 1 (IV-3
and V-118) for sequencing using the TruSeq Nano DNA Library Preparation Kit
(Illumina). Mapping of 150 bp, paired-end sequence reads to the UCSC hg19 build
of the genome and calling of single nucleotide variants from whole-genome
sequencing (WGS) data generated using an Illumina HiSeqX10 platform (King-
horn Centre for Clinical Genomics, Sydney, Australia), was performed as pre-
viously described with the minor modification of using the Genome Analysis
Toolkit (GATK) version 3.8 software27,28. Filtering of both coding and non-coding
variants within the chr2 linkage interval shared between both individuals under a
dominant model and absent from the gnomAD variant database29 at a frequency
>0.001 was performed using the bcftools isec command from htslib v1.9. Single



























































Control (n = 4) FAME (n = 4)
Ex3–4STARD7
Fig. 3 Expression of STARD7 is unaltered in patient-derived skin fibroblasts. a Graph shows average STARD7 expression by relative standard curve
quantitative PCR (qPCR) normalised to HPRT1 expression in fibroblast cell lines from four control donors (white bars) and four affected male individuals
from Family 1 (IV-52, V-118, V-124 and V-161; black bars). Individual data points overlay the each bar. Tests for significance were performed using Student’s
two-tailed t-test assuming unequal variances (p= 0.50 Exon 1–2; p= 0.85 Exon 3–4). b Western blot of STARD7 protein compared to β-actin on the same
blot of fibroblasts from the same four individuals from Family 1 as assayed by qPCR and two male control donors (C1 and C2). Data underlying this figure
are available in Source Data
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containing the expanded repeat were visualised using the Integrative Genomics
Viewer (IGV) v2.4.5 with soft-clipped reads unmasked31.
Rome: WGS library was prepared from the genomic DNA of the individual
(PM195; Family 4) by using TruSeq DNA PCR-Free KIT (Illumina, San Diego, CA,
USA) and sequenced 150 bp paired-end reads on an Illumina HiSeq producing
470,174,247 fragments, corresponding to about 39X coverage after mapping and
removal of duplicated reads. Reads were quality filtered and aligned to the
reference human genome sequence (GRCh38/hg38) with BWA-MEM v.0.7.1532.
Resulting BAM files underwent local realignment around insertion-deletion sites,
duplicate marking and recalibration steps with GATK v3.828. Variant calling was
performed with HaplotypeCaller v3.8 with standard parameters, and output VCF
files were recalibrated with VariantRecalibrator from GATK v3.8. Genomic variant
annotation was carried out with VarSeq v1.4.7 (Golden Helix, Inc., Bozeman, MT,
www.goldenhelix.com) and only variants with a minimum read depth of 5X were
included in the downstream analysis. Thereafter, only variants in the
pericentromeric region of interest of chr2 (chr2: 91,800,000–106,700,000) were
considered.
Prioritisation of variants of potential interest was carried out through three
distinct analyses. For the first analysis, all variants reported to be pathogenic or
potentially pathogenic in the clinical databases of ClinVar, HGMD Professional
v2017.2 and/or Centogene CentoMD v4.1 were retained. For the second analysis, we
focused on variants in exonic regions without a reported clinical annotation. We
excluded variants with a population frequency above 1% in the databases of 1000
Genomes Project, National Heart, Lung and Blood Institute (NHLBI, https://www.
nhlbi.nih.gov/) Exome Sequencing Project (ESP, http://evs.gs.washington.edu/),
ExAC (Exome Aggregation Consortium, http://exac.broadinstitute.org/) and
gnomAD (The Genome Aggregation Database, https://gnomad.broadinstitute.org/),
along with variants recorded in the Personal Genomics internal database. We
retained all the non-synonymous variants predicted to alter the protein structure or
function by at least three of the following in silico prediction tools: Mutation Taster,
SIFT, Polyphen-2, MutationAssessor and FATHMM. For the third analysis, we
prioritised the variants outside exonic regions by considering rare variants
(frequency below 1% in frequency population databases, including the Personal
Genomics internal database) and with a predicted significant effect on the protein
structure or function by at least three of the in silico prediction tools. Variants were
then prioritised by considering their presence in regulatory regions as reported in
the ENCODE database (https://www.encodeproject.org/). The manual inspection
of the BAM files, by using Integrative Genomics Viewer (IGV), allowed us to
evaluate the coverage of the variants and the quality of the aligned reads.
The identification of putative genomic expansions, structural variants or copy
number variations was carried out by using Lumpy v0.2.1333 and Manta v1.2.234
software. The ExpansionHunter tool v2.5.314 was adopted to estimate the size of
potential repetitions of short unit sequences.
Long-read sequencing. DNA was extracted for all long-read sequencing pro-
tocols using the QIAsymphony system from skin fibroblasts (passage 6) cultured
in Dulbecco’s modified Eagle’s Medium (DMEM; Life Technologies) with 10%
fetal calf serum. Pacific Biosciences (PacBio) single molecule real-time (SMRT)
sequencing data were obtained in two batches: In the first batch, two Australian
FAME2 carriers (Family 1: IV-44 and IV-98) were sequenced with two flow cells
per sample. Resulting bam files were converted to fastq using the SMRT Link
software v5.1.0 bam2fastq program. Resulting fastq files were either mapped
directly to the human genome hg38 build using NGM-LR35 with structural
variants called by Sniffles35 or used as input for de novo assembly with Canu
v1.7. In the second batch, a single sample (Family 1: IV-98) was sequenced. DNA
fragment sizes were determined with the Femto Pulse capillary electrophoresis
system (Agilent Technologies, Santa Clara, CA). DNA fragments of size greater
than 6 kb were selected with BluePippin (Sage Science, Beverly, MA) pulsed field
gel electrophoresis system. Sequencing was carried out for 20 h per SMRT cell on
the Sequel system with Binding Kit 3.0 (PacBio, 101–500–400) and Sequencing
Kit 3.0 (PacBio 101–427–800). Circular consensus calling was performed using
CCS 3.2.1 software. Reads were mapped to the GRCh38 build of the human
genome using pbmm2 with “-c 0 -L 0.01” for CCS reads and “-c 0 -L 0.1”
for subreads.
Oxford nanopore data were obtained for DNA samples extracted from
fibroblasts from two individuals from Family 1, as described above, and two from
Family 5 (II-37 and IV-29 Fig. S2e). For each of the four participant samples, 3 µg
of DNA was prepared for Oxford Nanopore 1D genomic sequencing by ligation
using the SQK-LSK108 kit and was run on a FLO-MIN106 flow cell for 48 h.
Basecalling was performed on MinKNOW 18.01.6 with MinKNOW Core 1.11.5
and Albacore v2.1. Data were either mapped with NGM-LR or assembled with
Canu v1.7 as described below, using suggested settings for nanopore
sequencing reads.
De novo whole-genome assembly of one individual with input of both PacBio
and nanopore sequencing from one individual from Family 1 was carried out using
the Canu v1.7 assembler with default starting parameters for a genome size of 3.6
Gbp. Recalibrated reads from Canu were mapped to the hg38 build of the human
genome using NGM-LR as described above.
Repeat expansion analysis. WGS was performed for two affected individuals
from Family 1 on the Illumina HiSeq X10 platform, one individual from Family 3
as described above, and three affected individuals from Family 19 on the Illumina
HiSeq platform. A cohort of 69 individuals without FAME were used for com-
parison, with 150 bp paired-end sequencing performed on the Illumina HiSeq
X platform (Kinghorn Centre for Clinical Genomics, Sydney, Australia). Library
preparation for 53 of the samples used the Illumina TruSeq Nano DNA HT Library
Preparation Kit; the other 16 samples used KAPA Hyper Prep Kit PCR-free library
preparation.
Reads were aligned to the hg19 reference genome with BWA-MEM v0.7.17-
r118832, then duplicate marking, local realignment and recalibration were
performed with GATK v4.0.3.028. Repeat expansion analysis targeting two FAME2
loci, the ATTTT repeat and predicted ATTTC insertion in STARD7, was
performed using ExpansionHunter v2.5.514 and exSTRa v0.88.3 with Bio-STR-
exSTRa v1.0.115. Custom files defining the FAME2-AAAAT and FAME2-AAATG
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Fig. 4 Expression patterns of ATTTC repeat genes in brain, skin fibroblast and lymphoblastoid cell lines. The heatmap shows relative gene expression
expressed as transcripts per kilobase per million mapped reads (TPM) based on the colour scale as shown. Data and image downloaded from the GTEx
Portal https://www.gtexportal.org
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Supplementary Figure 1 shows the repeat sizes predicted by ExpansionHunter
and empirical cumulative distribution function of repeated bases from exSTRa for
the two FAME2 loci. Significance testing was performed using the exSTRa
tsum_test function with 100,000 permutations in case-control mode comparing
each affected individual with FAME to the 69 unaffected individuals without
FAME. All FAME2 carriers were significant outliers for the FAME2-AAATG locus
(p < 0.0001 for all individuals) while only four samples were significant outliers (p
< 0.05) for the FAME2-AAAAT locus.
RNA-Seq. Total RNA was extracted from patient-derived primary skin fibroblasts
of four Australian/New Zealand FAME, two Italian FAME and four age-matched
controls using QIAGEN RNeasy kits, as per the manufacturer’s protocol. Library
preparation and RNA-Seq were performed as a service by the UCLA Neuroscience
Genomics Core Facility. The TruSeq v2 kit (Illumina) was used to generate un-
stranded libraries with 150-bp mean fragment sizes and 50-bp paired-end
sequencing performed using the HiSeq2500 (Illumina). Sequence data were map-
ped to the GRCh38 build of the human genome using HISAT2 v2.1.036. Read
counts were generated with StringTie v1.3.336. Differential expression between
FAME and control samples was determined using the exact test from the edgeR
v3.26.5 package in R v3.6.037. Differentially expressed genes were filtered to false
discovery rate (FDR) < 0.05 and log base 2-fold change (LFC) >= 1 or <=−1.
Quantitative PCR. RNA was extracted from four patient-derived primary skin
fibroblast cell lines from Family 1 and four control fibroblast cell lines from adult
donors not affected by FAME as described above under RNA-Seq. cDNA were
generated from 1 μg of total RNA using the iScript reverse transcription kit (Bio-
Rad, Gladesville, NSW, Australia; cat# 1708891), according to the manufacturer’s
protocol.
Quantification of differentially expressed transcripts was performed with the
relative standard curve method using SYBR green fluorescence intensity for
detection. Products were amplified in 1 × iTaq Universal SYBR Green supermix
(Bio-Rad; cat# 1725121) with primers at 1μM final concentration. Each sample and
standard was amplified with three technical replicates on an Applied Biosystems
StepOnePlus. Expression values were determined relative to a dilution curve of a
cDNA standard made from pooled control fibroblast cDNA. Specificity of products
was determined by melt curve analysis at the conclusion of each run. Expression
values of each gene were normalised to HPRT1 expression values from the same
sample.
Western blotting. Fibroblasts were cultured as described in Supplementary
methods then lysed with lysis buffer (150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 0.25% Sodium deoxycholate, 50 mM Tris. Added protease inhibitor, 50 mM
NaF and 0.1 mM Na3VO4). Extracts were separated by 4–12% polyacrylamide gel
and transferred to nitrocellulose membrane by electroblotting. STARD7 was
detected with rabbit polyclonal anti-human/mouse/rat STARD7 (Proteintech cat#
15689–1-AP) at 1:500 dilution followed by anti-rabbit IgG conjugated to horse-
radish peroxidase (HRP) at 1:2000 (Dako cat# P0448). Enhanced chemilumines-
cent detection (Bio-Rad cat# 1705061) was visualised with the chemidoc detection
system (Bio-Rad). Full blots are available in the Source Data file.
PCR amplification and sequencing of repeats (Rome). Pentanucleotide repeats
were analysed in duplicate by long-range PCR with Expand Long Template PCR
System (Roche) according to the manufacturer’s recommendation. Some 200 ng
genomic DNA were amplified with primers STARD7F and STARD7R (300 nM),
dNTP (350 µM) buffer 1 (1×) Enzyme 0.5 U (×50 µl reaction). After 2 min of initial
denaturation at 94 °C, DNA samples underwent 10 cycles of amplification (dena-
turation 94 °C for 10 s, annealing 56 °C for 30 s, elongation 68 °C 3min) followed
by an additional 20 cycles (94 °C for 15 s, annealing 56 °C for 30 s, elongation 68 °C
45 s+ 20 s each cycle elongation for each successive cycle). PCR products were
separated by electrophoresis on 1% agarose gel. DNA was extracted from the
agarose gel slice and the number of repeat units was determined by Sanger
sequencing (Eurofins Genomics Sequencing Service).
Repeat-primed PCR. Primers for both Adelaide and Rome are shown in Sup-
plementary Table 3.
Adelaide: Reaction mixes included 100 ng genomic DNA, 0.5 µM FAM-labelled
locus specific (RP-PCR-FAME2-P1 or P2) and RP-PCR-P3 primers, and 0.05 µM
repeat specific primer (one of RP-PCR-FAME2–4.5 to 4.8) with Expand Long
Template polymerase (Roche, cat# 25524324) or Taq polymerase (Roche, cat#
18697220). The initial RP-PCR step was at 95 °C for 5 min followed by 10 cycles
(95 °C for 30 s, 48 °C+ 1.0 °C each cycle for 45 s and 65 °C+ 1.0 °C each cycle for
5 min) continuing to 30 cycles (95 °C for 30 s, 58 °C for 1 min and 72 °C for 5 min)
and ending with 72 °C for 7 min. Fragment analysis was performed on the RP-PCR
products with an ABI3730 DNA analyser.
Rome: The pentanucleotide repeat sequence in STARD7 gene was amplified by
ATTTT and ATTTC RP-PCR with the following primers: STARD7R* 5′FAM-
labelled (locus specific primer), RP-PCR-STARD7-P3 (generic primer) and RP-
PCR-STARD7-P4 primers specific for the short pentanucleotide repeat (ATTTT)
and for the possible expanded (ATTTC) repeat or possible (ATTTC) repeat
interruption. PCR was performed with 100 ng DNA, 1.5 mM MgCl2, 200 µM
dNTP, 0.4 µM locus specific primer, 0.4 µM generic primer, 0.2 µM repeat primer,
2.5 U Polymed Taq in 25 µl volume. The initial PCR step was at 94 °C for 15 min
followed by 35 cycles (94 °C for 45 s, 60 °C for 30 s and 72 °C for 2 min) and 72 °C
elongation for 30 min. Capillary electrophoresis was performed on ABI310 GEN
ANALYZER (Applied Biosystems).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Source data for Figs. 1a, 3a, 3b, Supplementary Figs. 1a, b and 4b are provided in the
Source Data files of this manuscript. RNA-Seq data are available from the NCBI
BioProject PRJNA563467. Whole-genome sequencing data are available from the
corresponding author on request, subject to human research ethics approval and patient
consent.
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